Skip to main content
Equibles
BBLG logo

BBLG · Bone Biologics Corp · Metrics

Track BBLG — free

Use BBLG with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research BBLG.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$0.48 +0.00 (+0.97%)
Rebalance outlook locked
Going-concern doubt — flagged Aug 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“These factors raise substantial doubt about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.”
View the 10-Q filed Aug 14, 2026
Market Cap
$1.37M
Shares
2.76M
Volume · Oct 5 22.81K Avg daily vol (3M) 384.68K

BBLG metrics

54 of 115 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$0.48
Market cap
$1.37M

Price action

20 metrics
Price change (1W)
-4.2%
Price change (30D)
-15.1%
Price change (3M)
-66.5%
Price change (6M)
-61.7%
Price change (YTD)
-67.2%
Price change (1Y)
-81.4%
Trailing year
Price change (5Y)
—
52-week high
$2.70
52-week low
$0.48
Change from 52-week high
-82.4%
Change from 52-week low
+0.1%
Annualized volatility
66.1%
Annualized volatility (3M)
74.8%
Beta
1.1
RSI (14D)
27.8
Price vs SMA 50
-27.8%
Price vs SMA 200
-60.0%
Avg volume (3M)
384,677
Relative volume
0.1
Average dollar volume
$250,840

Company

3 metrics
Sector
Healthcare
Industry
Biotechnology
Shares outstanding
2.76M

Valuation

12 metrics
P / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
—
EV / EBITDA
—
EV / EBIT
—
P / sales
0.0×
reciprocal yield 78,226.0%
P / book
0.3
reciprocal yield 286.9%
FCF yield
—
TTM · current market cap
Buyback yield
—
P / FCF
—
P / operating cash flow
—
Earnings yield
-211.4%

Historical valuation

8 metrics
P / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
—
EV / revenue historical average (5Y)
—
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
—

Profitability

9 metrics
Gross margin
—
Operating margin
-0.1%
Trailing 12 months
Net margin
-0.2%
Gross profit (TTM)
—
Operating profit (TTM)
−$3.06M
Net income (TTM)
−$2.89M
Trailing 12 months
Diluted EPS (TTM)
$-0.26
FCF margin
—
Effective tax rate
—

Per share

11 metrics
Revenue per diluted share (TTM)
—
Gross profit per diluted share (TTM)
—
Operating profit per diluted share (TTM)
—
EBITDA per diluted share (TTM)
—
Net income per diluted share (TTM)
—
Operating cash flow per diluted share (TTM)
—
Free cash flow per diluted share (TTM)
—
Capital expenditures per diluted share (TTM)
—
R&D per diluted share (TTM)
—
Stock compensation per diluted share (TTM)
—
Book value per share
$3.00

Growth

11 metrics
Revenue growth YoY
+0.0%
Year over year
Net income growth YoY
—
Revenue (TTM)
$1.07B
Trailing 12 months
EPS growth YoY
—
Shares change YoY
+222.1%
Year over year · more shares
Revenue CAGR (3Y)
—
Revenue CAGR (5Y)
—
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—

Quality

14 metrics
Return on equity
-73.7%
Return on assets
-65.2%
Debt / equity
—
Current ratio
8.7
EBITDA (TTM)
—
Free cash flow (TTM)
—
Quick ratio
8.7
Interest coverage
—
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$6.19M
Latest balance sheet
Cash & equivalents
$6.19M
Total assets
$4.44M
Total debt
—

Cash flow & spend

7 metrics
Operating cash flow (TTM)
−$2.63M
Capital expenditures (TTM)
$504
R&D (TTM)
$895,351
SG&A (TTM)
—
Stock compensation (TTM)
$164,612
R&D / revenue
—
Stock compensation / revenue
—

Ownership (13F)

3 metrics
13F filers
4
13F filer change QoQ
0
Institutional ownership
1.9%

Short interest

3 metrics
Short interest
1.3%
Latest settlement · 1.0 days to cover
Days to cover
1.0d
Short-squeeze score
42 / 100

Insider activity

2 metrics
Net insider buying (90D)
—
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
Flagged
Key facts CIK 1419554 CUSIP 098070600 Visit website Investor relations